SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
the appointment of Mohammad
Ahmadian, Ph.D., as Vice President, Chemistry and
Pharmaceutical Development. In his role, Dr. Ahmadian will assist
in managing research and development of the Company's drug
candidates, including RGLS8429, which is being developed for
patients with autosomal dominant polycystic kidney disease (ADPKD),
and will add significant expertise to Regulus' existing scientific
talent.
![Regulus Therapeutics Inc. Logo Regulus Therapeutics Inc. Logo](https://mma.prnewswire.com/media/370141/regulus_logo_finalnew_Logo.jpg)
"We are excited to welcome Moh to the Regulus team," said
Denis Drygin, Chief Scientific
Officer of Regulus. "Moh brings over 20 years of drug discovery and
development experience to the company and we believe his background
working specifically with oligonucleotides makes him uniquely
qualified for the position. We look forward to drawing on his
expertise as we continue to make strides in developing RGLS8429, as
well as our research programs."
Prior to joining Regulus, Dr. Ahmadian was Vice President &
Resident Director of Kinovate Life Sciences, Inc., where in
addition to serving as the technical lead, he was responsible for
operations, including overseeing production, quality control,
quality assurance and the supply chain. Prior to Kinovate, Dr.
Ahmadian was employed with Nitto Denko Technical Corporation where
he managed various projects concerning design, manufacturing and
process development of therapeutic oligonucleotides. Previously he
worked for various life sciences companies as a research chemist
and manager of RNA chemistry projects. Dr. Ahmadian holds a Ph.D.
in medicinal chemistry from Purdue
University and an M.Sc. in organic chemistry from
Ball State University.
Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
In connection with his hiring on December
1, 2021, Dr. Ahmadian received an option to purchase 200,000
shares of Regulus' common stock, with an exercise price of
$0.36 per share, which is equal to
the fair market value on the grant date. The option has a 10-year
term and vests over a period of four years, with 25% vesting on
December 1, 2022, which is one year
following the date of grant and the remaining 75% vesting ratably
over the succeeding thirty-six months, subject to Dr. Ahmadian's
continuous service through each vesting date, and subject to the
terms and conditions of Regulus' Inducement Plan and stock option
grant notice and agreement thereunder.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate
headquarters in San Diego,
CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements associated with the Company's employees
and their potential impact on our research and development
programs. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe
and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and the risk additional
toxicology data may be negative. In addition, while Regulus expects
the COVID-19 pandemic to adversely affect its business operations
and financial results, the extent of the impact on Regulus' ability
to achieve its preclinical and clinical development objectives and
the value of and market for its common stock, will depend on future
developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the
pandemic, travel restrictions, quarantines, social distancing and
business closure requirements in the U.S. and in other countries,
and the effectiveness of actions taken globally to contain and
treat the disease. These and other risks are described in
additional detail in Regulus' filings with the Securities and
Exchange Commission, including under the "Risk Factors" heading of
Regulus most recently quarterly report on Form 10-Q. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Regulus undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-appoints-mohammad-ahmadian-phd-as-vice-president-chemistry-and-pharmaceutical-development-301436939.html
SOURCE Regulus Therapeutics Inc.